Organ transplantation is an effective treatment to end-stage organ disease, which provides survival opportunity for the patient. However, immune rejection after transplantation has become the biggest obstacle to successful treatment,and it is the primary challenge for transplantation. HO-1 is the body's metabolic rate-limiting enzyme of heme,the protective effect of which to organ transplantation has been widely recognized. Through the induction of HO-1 over-expression in vivo, promotion of Foxp3 gene expression, stimulating the expression of scurfin protein, increasing the number of Foxp3+ Treg in the spleen and peripheral blood, increasing CD4+ CD25+ T cells, and inhibition of CD4+T,CD8+T cells, inhibition of immune rejection in organ transplantation can be a-chieved, at the same time the graft ischemia-reperfusion injury can be reduced, cell damage can be alleviated, the survival rate of transplanted organs and patients' quality of life can be improved, which opens up the new way for the success of organ transplantation.%器官移植是器官疾病终末期治疗的有效途径,为患者提供再次生存的机会,但移植后免疫排斥又成为治疗成功的最大障碍,是移植界面临的首要难题.血红素氧化酶1(HO-1)是体内血红素代谢分解的限速酶,其在移植后的器官保护作用已被普遍认知.通过诱导HO-1在体内过度表达,促进Foxp3基因的表达,刺激scurfin蛋白表达,增加脾脏及外周血中Foxp3 +T调节细胞(Foxp3 +Treg)数量,增加CD4 +CD25 +T细胞,抑制CD4 +、CD8 +T细胞,从而达到抑制器官移植免疫排斥的目的,同时还能减轻移植物缺血/再灌注损伤、缓解细胞损伤,提高移植器官存活率,改善患者生活质量.
展开▼
